Montana Medicaid spending on GLP-1 drugs

How much did Montana Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $22.2 million for GLP-1 drugs paid through Montana Medicaid in 2025, across at least 22,719 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 47 rows of 139, so these figures are floors.

Pharmacies were reimbursed at least $5.7 million for GLP-1 drugs paid through Montana Medicaid in 2026 (quarter 1 only, as posted so far), across at least 5,674 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 11 rows of 33, so these figures are floors.

By year and ingredient

2020at least $669,225No data$4,162,347at least $913,477at least $2,621,551Suppressedat least $10,840at least $8,377,440
2021at least $1,914,060No data$5,354,684at least $3,524,356at least $1,011,880SuppressedSuppressedat least $11,804,980
2022at least $4,129,556at least $27,083$4,385,055at least $8,350,318at least $200,556SuppressedSuppressedat least $17,092,568
2023at least $9,173,419at least $545,703$3,176,453at least $8,356,160at least $70,762SuppressedNo dataat least $21,322,497
2024at least $13,196,090$1,762,286$1,138,968at least $4,967,395at least $23,552SuppressedNo dataat least $21,088,290
2025at least $15,238,381at least $3,062,809at least $382,772$3,501,301at least $9,845No dataNo dataat least $22,195,107
2026 (Q1)at least $4,049,045at least $764,138at least $54,375$866,230No dataNo dataNo dataat least $5,733,788

By product, 2025

Ozempicat least $14,885,482at least 15,2637 of 19
Rybelsusat least $152,364at least 1614 of 13
Wegovyat least $200,535at least 15312 of 20
Mounjaro$3,024,2672,8680 of 24
Zepboundat least $38,542at least 369 of 12
Liraglutide (generic name listing)at least $168,044at least 25811 of 22
Victoza$214,7273300 of 8
Trulicity$3,501,3013,6380 of 16
Bydureonat least $9,845at least 121 of 2
ByettaSuppressedSuppressed2 of 2
Exenatide (generic name listing)SuppressedSuppressed1 of 1

By quarter, 2025

Q1 2025at least $5,258,498at least 5,44012 of 35
Q2 2025at least $5,665,092at least 5,8019 of 35
Q3 2025at least $5,671,398at least 5,77611 of 34
Q4 2025at least $5,600,119at least 5,70215 of 35

By quarter, 2026 (posted so far)

Q1 2026at least $5,733,788at least 5,67411 of 33

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.